Hungary · Delayed Price · Currency is HUF Gedeon Richter Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
-
Pharma sales grew 10.7% in H1 2025, with clean EBIT up 15% and Women's Health leading segment growth. Inventory write-offs and FX losses impacted cash flow, but guidance for 10% revenue and EBIT growth remains on track. Renewable energy and R&D investments advanced strategic goals.
-
Q1 2025 saw strong revenue and EBIT growth, driven by pharma sales and FX gains, with robust free cash flow and a solid cash position. Four biosimilar launches are planned within 12 months, and the outlook for general medicines and women's health remains positive.
Fiscal Year 2024
-
Revenue and profit grew strongly in 2024, with all business units contributing and free cash flow nearly tripling. 2025 guidance targets 10% growth amid lower milestone income and cost control initiatives.
-
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
-
Recent acquisitions have enabled full integration and R&D expansion in women's healthcare, positioning the business as a European leader with ambitious growth targets. The company is focused on realistic commercialization, internal innovation, and achieving over 20% EBIT margins after initial investments.